L Jenkins, U Jungwirth, A Avgustinova, M Iravani… - Cancer research, 2022 - AACR
Immune-checkpoint blockade (ICB) promotes antitumor immune responses and can result in durable patient benefit. However, response rates in breast cancer patients remain modest …
A Vienot, JR Pallandre, E Renaude, J Viot… - …, 2022 - Taylor & Francis
Combining immunogenic cell death-inducing chemotherapies and PD-1 blockade can generate remarkable tumor responses. It is now well established that TGF-β1 signaling is a …
M Cabo, S Santana-Hernández, M Costa-Garcia… - Cancer immunology …, 2021 - AACR
Enhancing natural killer (NK) cell–based cancer immunotherapy by overcoming immunosuppression is an area of intensive research. Here, we have demonstrated that the …
H Tokuyama, T Hagi, SR Mattarollo… - … journal of cancer, 2008 - Wiley Online Library
Abstract Vγ9Vδ2 T cells exert potent cytotoxicity toward various tumor cells and adoptive transfer of Vγ9Vδ2 T cells is an attractive proposition for cell based immunotherapy. Vγ9Vδ2 …
Y Shi, X Fan, H Deng, RJ Brezski… - The Journal of …, 2015 - journals.aai.org
Trastuzumab has been used for the treatment of HER2-overexpressing breast cancer for more than a decade, but the mechanisms of action for the therapy are still being actively …
EI Rivas, J Linares, M Zwick, A Gómez-Llonin… - Nature …, 2022 - nature.com
About 50% of human epidermal growth factor receptor 2 (HER2)+ breast cancer patients do not benefit from HER2-targeted therapy and almost 20% of them relapse after treatment …
Z Ang, L Paruzzo, KE Hayer, C Schmidt, M Torres Diz… - Blood, 2023 - ashpublications.org
Aberrant skipping of coding exons in CD19 and CD22 compromises the response to immunotherapy in B-cell malignancies. Here, we showed that the MS4A1 gene encoding …
F Shojaei, X Wu, X Qu, M Kowanetz… - Proceedings of the …, 2009 - National Acad Sciences
Recent studies suggest that tumor-associated CD11b+ Gr1+ myeloid cells contribute to refractoriness to antiangiogenic therapy with an anti-VEGF-A antibody. However, the …
JP Joshi, NE Brown, SE Griner, R Nahta - Biochemical pharmacology, 2011 - Elsevier
Resistance to the anti-HER2 monoclonal antibody trastuzumab is a major problem in the treatment of HER2-overexpressing metastatic breast cancer. Growth differentiation factor 15 …